Effects of antiretroviral therapy on cognitive impairment

Current HIV/AIDS Reports

Volumn 5, Issue 2, 2008, Pages 64-71

  Liner II, Kevin J ^b   Hall, Colin D ^b   Robertson, Kevin R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; BETA 2 MICROGLOBULIN; COLONY STIMULATING FACTOR 1; EFAVIRENZ; GELATINASE A; GELATINASE B; ICOSANOID; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MATRILYSIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NELFINAVIR; NEOPTERIN; NEVIRAPINE; PROTEINASE INHIBITOR; QUINOLINIC ACID; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TUMOR NECROSIS FACTOR; ZIDOVUDINE;

BLOOD BRAIN BARRIER; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEMENTIA; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; DRUG RESISTANCE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INCIDENCE; MACROPHAGE; MONOCYTE; NEUROPROTECTION; PREVALENCE; REVIEW; VIRUS LOAD; VIRUS RESISTANCE;

EID: 43249127226     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-008-0011-7     Document Type: Review

References (61)

1. 1. R.W. Price B.A. Navia E.S. Cho 1986 AIDS encephalopathy Neurol Clin 4 285 301 2425241 1:STN:280:DyaL283lslSguw%3D%3D Price RW, Navia BA, Cho ES: AIDS encephalopathy. Neurol Clin 1986, 4: 285–301.
2. 2. A. Antinori G. Arendt J.T. Becker 2007 Updated research nosology for HIV-associated neurocognitive disorders Neurology 69 1789 1799 17914061 10.1212/01.WNL.0000287431.88658.8b 1:STN:280:DC%2BD2snktFyqsQ%3D%3D Antinori A, Arendt G, Becker JT, et al.: Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69: 1789–1799.
3. 3. B.A. Navia B.D. Jordan R.W. Price 1986 The AIDS dementia complex: I. Clinical features Ann Neurol 19 517 524 3729308 10.1002/ana.410190602 1:STN:280:DyaL283mslCgsg%3D%3D Navia BA, Jordan BD, Price RW: The AIDS dementia complex: I. Clinical features. Ann Neurol 1986, 19: 517–524.
4. 4. R.A. Bornstein H.A. Nasrallah M.F. Para 1993 Neuropsychological performance in symptomatic and asymptomatic HIV infection AIDS 7 519 524 8507418 10.1097/00002030-199304000-00011 1:STN:280:DyaK3s3otlSlsA%3D%3D Bornstein RA, Nasrallah HA, Para MF, et al.: Neuropsychological performance in symptomatic and asymptomatic HIV infection. AIDS 1993, 7: 519–524.
5. 5. Y. Stern M.P. McDermott S. Albert 2001 Factors associated with incident human immunodeficiency virus-dementia Arch Neurol 58 473 479 11255452 10.1001/archneur.58.3.473 1:STN:280:DC%2BD3M7pvVChsw%3D%3D Stern Y, McDermott MP, Albert S, et al.: Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol 2001, 58: 473–479.
6. 6. P. Portegies R.H. Enting J. Gans de 1993 Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, the Netherlands AIDS 7 669 675 8318174 10.1097/00002030-199305000-00010 1:STN:280:DyaK3szgsFaitg%3D%3D Portegies P, Enting RH, de Gans J, et al.: Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, the Netherlands. AIDS 1993, 7: 669–675.
7. 7. N. Sacktor M.P. McDermott K. Marder 2002 HIV-associated cognitive impairment before and after the advent of combination therapy J Neurovirol 8 136 142 11935465 10.1080/13550280290049615 1:CAS:528:DC%2BD38XlslKqs74%3D Sacktor N, McDermott MP, Marder K, et al.: HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002, 8: 136–142.
8. 8. N.K. Saksena T.K. Smit 2005 HAART and the molecular biology of AIDS dementia complex Indian J Med Res 121 256 269 15817943 1:CAS:528:DC%2BD2MXltVSqt70%3D Saksena NK, Smit TK: HAART and the molecular biology of AIDS dementia complex. Indian J Med Res 2005, 121: 256–269.
9. 9. N. Sacktor R.H. Lyles R. Skolasky 2001 HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998 Neurology 56 257 260 11160967 1:STN:280:DC%2BD3M7pt1yhuw%3D%3D Sacktor N, Lyles RH, Skolasky R, et al.: HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 2001, 56: 257–260.
10. 10. J.W. Dilley S. Schwarcz L. Loeb 2005 The decline of incident cases of HIV-associated neurological disorders in San Francisco, 1991–2003 AIDS 19 634 635 15802986 10.1097/01.aids.0000163944.39306.7c Dilley JW, Schwarcz S, Loeb L, et al.: The decline of incident cases of HIV-associated neurological disorders in San Francisco, 1991–2003. AIDS 2005, 19: 634–635.
11. 11. K.R. Robertson T.D. Parsons J.J. Sidtis 2006 Timed gait test: normative data for the assessment of the AIDS dementia complex J Clin Exp Neuropsychol 28 1053 1064 16840235 10.1080/13803390500205684 Robertson KR, Parsons TD, Sidtis JJ, et al.: Timed gait test: normative data for the assessment of the AIDS dementia complex. J Clin Exp Neuropsychol 2006, 28: 1053–1064.
12. 12. K.R. Robertson W.T. Robertson S. Ford 2004 Highly active antiretroviral therapy improves neurocognitive functioning J Acquir Immune Defic Syndr 36 562 566 15097298 10.1097/00126334-200405010-00003 Robertson KR, Robertson WT, Ford S, et al.: Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004, 36: 562–566.
13. 13. N. Sacktor N. Nakasujja R. Skolasky 2006 Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa Neurology 67 311 314 16864825 10.1212/01.wnl.0000225183.74521.72 1:STN:280:DC%2BD28vktFOjtw%3D%3D Sacktor N, Nakasujja N, Skolasky R, et al.: Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology 2006, 67: 311–314.
14. 14. G. Villa A. Solida E. Moro 1996 Cognitive impairment in asymptomatic stages of HIV infection. A longitudinal study Eur Neurol 36 125 133 8738940 10.1159/000117228 1:STN:280:DyaK28zivVKktw%3D%3D Villa G, Solida A, Moro E, et al.: Cognitive impairment in asymptomatic stages of HIV infection. A longitudinal study. Eur Neurol 1996, 36: 125–133.
15. 15. K.R. Robertson M. Smurzynski T.D. Parsons 2007 The prevalence and incidence of neurocognitive impairment in the HAART era AIDS 21 1915 1921 17721099 10.1097/QAD.0b013e32828e4e27 Robertson KR, Smurzynski M, Parsons TD, et al.: The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007, 21: 1915–1921.
16. 16. T.D. Langford S.L. Letendre G.J. Larrea E. Masliah 2003 Changing patterns in the neuropathogenesis of HIV during the HAART era Brain Pathol 13 195 210 12744473 1:CAS:528:DC%2BD3sXjsF2gurY%3D Langford TD, Letendre SL, Larrea GJ, Masliah E: Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 2003, 13: 195–210.
17. 17. J.K. Neuenburg H.R. Brodt B.G. Herndier 2002 HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy J Acquir Immune Defic Syndr 31 171 177 12394795 Neuenburg JK, Brodt HR, Herndier BG, et al.: HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 31: 171–177.
18. 18. L. Chang T. Ernst M.D. Witt 2003 Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART Antivir Ther 8 17 26 12713060 1:CAS:528:DC%2BD3sXktVSgtbg%3D Chang L, Ernst T, Witt MD, et al.: Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antivir Ther 2003, 8: 17–26.
19. 19. H.R. Brodt B.S. Kamps P. Gute 1997 Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy AIDS 11 1731 1738 9386808 10.1097/00002030-199714000-00010 1:STN:280:DyaK1c%2FkvVSguw%3D%3D Brodt HR, Kamps BS, Gute P, et al.: Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997, 11: 1731–1738.
20. 20. G.J. Dore A. McDonald Y. Li 2003 Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy AIDS 17 1539 1545 12824792 10.1097/00002030-200307040-00015 Dore GJ, McDonald A, Li Y, et al.: Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003, 17: 1539–1545.
21. 21. M. Gisslen L. Hagberg 2001 Antiretroviral treatment of central nervous system HIV-1 infection: a review HIV Med 2 97 104 11737386 10.1046/j.1468-1293.2001.00056.x 1:CAS:528:DC%2BD3MXnsVCmur8%3D Gisslen M, Hagberg L: Antiretroviral treatment of central nervous system HIV-1 infection: a review. HIV Med 2001, 2: 97–104.
22. 22. S. Ferrando W. Gorp van M. McElhiney 1998 Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function AIDS 12 F65 F70 9631133 10.1097/00002030-199808000-00002 1:STN:280:DyaK1c3psVGqtg%3D%3D Ferrando S, van Gorp W, McElhiney M, et al.: Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 1998, 12: F65–F70.
23. 23. L.A. Cysique P. Maruff B.J. Brew 2006 Variable benefit in neuropsychological function in HIV-infected HAART-treated patients Neurology 66 1447 1450 16682686 10.1212/01.wnl.0000210477.63851.d3 Cysique LA, Maruff P, Brew BJ: Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006, 66: 1447–1450.
24. 24. T.K. Smit B.J. Brew W. Tourtellotte 2004 Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment J Virol 78 10133 10148 15331746 10.1128/JVI.78.18.10133-10148.2004 1:CAS:528:DC%2BD2cXnvVartr4%3D Smit TK, Brew BJ, Tourtellotte W, et al.: Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 2004, 78: 10133–10148.
25. 25. A. Antinori C.F. Perno M.L. Giancola 2005 Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma Clin Infect Dis 41 1787 1793 16288405 10.1086/498310 1:CAS:528:DC%2BD28Xitlantw%3D%3D Antinori A, Perno CF, Giancola ML, et al.: Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005, 41: 1787–1793.
26. 26. A. Luca De B.C. Ciancio D. Larussa 2002 Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals Neurology 59 342 347 12177366 De Luca A, Ciancio BC, Larussa D, et al.: Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology 2002, 59: 342–347.
27. 27. C. Eggers K. Hertogs H.J. Sturenburg 2003 Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration AIDS 17 1897 1906 12960822 10.1097/00002030-200309050-00008 Eggers C, Hertogs K, Sturenburg HJ, et al.: Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 2003, 17: 1897–1906.
28. 28. Letendre SL, Ellis RJ, Grant I, McCutchan JA; HNRC Group: The CSF concentration/IC50 ratio: a potential predictor of antiretroviral efficacy in the CNS [abstract 614]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL; February 4–8, 2001.
29. 29. M. Gisslen G. Norkrans B. Svennerholm L. Hagberg 1997 The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine J Infect Dis 175 434 437 9203666 1:CAS:528:DyaK2sXht1Ghu7c%3D Gisslen M, Norkrans G, Svennerholm B, Hagberg L: The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997, 175: 434–437.
30. 30. K.T. Tashima A.M. Caliendo M. Ahmad 1999 Cerembrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy J Infect Dis 180 862 864 10438381 10.1086/314945 1:CAS:528:DyaK1MXmtVyktLo%3D Tashima KT, Caliendo AM, Ahmad M, et al.: Cerembrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999, 180: 862–864.
31. 31. A. Lafeuillade C. Solas P. Halfon 2002 Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations HIV Clin Trials 3 27 35 11819183 10.1310/WMWL-6W9Y-PXV2-X148 Lafeuillade A, Solas C, Halfon P, et al.: Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002, 3: 27–35.
32. 32. C. Solas A. Lafeuillade P. Halfon 2003 Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients Antimicrob Agents Chemother 47 238 243 12499197 10.1128/AAC.47.1.238-243.2003 1:CAS:528:DC%2BD3sXis12ntg%3D%3D Solas C, Lafeuillade A, Halfon P, et al.: Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003, 47: 238–243.
33. 33. E.V. Capparelli D. Holland C. Okamoto 2005 Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV AIDS 19 949 952 15905676 10.1097/01.aids.0000171409.38490.48 1:CAS:528:DC%2BD2MXktlKlurs%3D Capparelli EV, Holland D, Okamoto C, et al.: Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 2005, 19: 949–952.
34. 34. A. Yilmaz D. Fuchs L. Hagberg 2006 Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study BMC Infect Dis 6 63 16566834 10.1186/1471-2334-6-63 1:CAS:528:DC%2BD28XktVCrtL0%3D Yilmaz A, Fuchs D, Hagberg L, et al.: Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study. BMC Infect Dis 2006, 6: 63.
35. 35. S. Kravcik G. Victor J.B. Angel 1999 Activity of the combination of nelfinavir and saquinavir against human immunodeficiency virus after failure of prior protease inhibitor therapy Clin Infect Dis 29 702 703 10530484 1:CAS:528:DyaK1MXmsVOgsb0%3D 10.1086/598671 Kravcik S, Victor G, Angel JB, et al.: Activity of the combination of nelfinavir and saquinavir against human immunodeficiency virus after failure of prior protease inhibitor therapy. Clin Infect Dis 1999, 29: 702–703.
36. 36. C.G. Filippi G. Sze S.J. Farber 1998 Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy Radiology 206 491 498 9457204 1:CAS:528:DyaK1MXktFGhurc%3D Filippi CG, Sze G, Farber SJ, et al.: Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology 1998, 206: 491–498.
37. 37. K. Ritola K. Robertson S.A. Fiscus 2005 Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia J Virol 79 10830 10834 16051875 10.1128/JVI.79.16.10830-10834.2005 1:CAS:528:DC%2BD2MXntFCqsb8%3D Ritola K, Robertson K, Fiscus SA, et al.: Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 2005, 79: 10830–10834.
38. 38. A. Antinori M.L. Giancola S. Grisetti 2002 Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients AIDS 16 1867 1876 12351946 10.1097/00002030-200209270-00003 1:CAS:528:DC%2BD38XnsVWmt7s%3D Antinori A, Giancola ML, Grisetti S, et al.: Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS 2002, 16: 1867–1876.
39. 39. S.L. Letendre J.A. McCutchan M.E. Childers 2004 Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders Ann Neurol 56 416 423 15349869 10.1002/ana.20198 Letendre SL, McCutchan JA, Childers ME, et al.: Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004, 56: 416–423.
40. 40. M.L. Giancola P. Lorenzini P. Balestra 2006 Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy J Acquir Immune Defic Syndr 41 332 337 16540934 10.1097/01.qai.0000197077.64021.07 Giancola ML, Lorenzini P, Balestra P, et al.: Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 41: 332–337.
41. 41. N. Sacktor R.L. Skolasky P.M. Tarwater 2003 Response to systemic HIV viral load suppression correlates with psychomotor speed performance Neurology 61 567 569 12939443 1:STN:280:DC%2BD3svgtFSgug%3D%3D Sacktor N, Skolasky RL, Tarwater PM, et al.: Response to systemic HIV viral load suppression correlates with psychomotor speed performance. Neurology 2003, 61: 567–569.
42. 42. L.A. Cysique P. Maruff B.J. Brew 2004 Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 61 1699 1704 15534181 10.1001/archneur.61.11.1699 Cysique LA, Maruff P, Brew BJ: Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 2004, 61: 1699–1704.
43. 43. D.W. Haas B.W. Johnson P. Spearman 2003 Two phases of HIV RNA decay in CSF during initial days of multidrug therapy Neurology 61 1391 1396 14638961 1:STN:280:DC%2BD3srmtFemsQ%3D%3D Haas DW, Johnson BW, Spearman P, et al.: Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Neurology 2003, 61: 1391–1396.
44. 44. S. Letendre J. Marquie-Beck E. Capparelli 2008 Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system Arch Neurol 65 65 70 18195140 10.1001/archneurol.2007.31 Letendre S, Marquie-Beck J, Capparelli E, et al.: Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008, 65: 65–70.
45. 45. Marra C, Sinha S, Clifford D, et al.: Suppression of HIV Replication in Plasma Requires Suppression of HIV Replication in CSF. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.
46. 46. J.D. Glass H. Fedor S.L. Wesselingh J.C. McArthur 1995 Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia Ann Neurol 38 755 762 7486867 10.1002/ana.410380510 1:STN:280:DyaK28%2FnsVWrtQ%3D%3D Glass JD, Fedor H, Wesselingh SL, McArthur JC: Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995, 38: 755–762.
47. 47. K.C. Williams S. Corey S.V. Westmoreland 2001 Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS J Exp Med 193 905 915 11304551 10.1084/jem.193.8.905 1:CAS:528:DC%2BD3MXivFOhtr8%3D Williams KC, Corey S, Westmoreland SV, et al.: Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 2001, 193: 905–915.
48. 48. S. Aquaro S. Panti M.C. Caroleo 2000 Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes J Leukoc Biol 68 429 435 10985261 1:CAS:528:DC%2BD3cXmsFWltrc%3D Aquaro S, Panti S, Caroleo MC, et al.: Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes. J Leukoc Biol 2000, 68: 429–435.
49. 49. A.D. Badley D. Dockrell M. Simpson 1997 Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor J Exp Med 185 55 64 8996241 10.1084/jem.185.1.55 1:STN:280:DyaK2s7kvFCgsQ%3D%3D Badley AD, Dockrell D, Simpson M, et al.: Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med 1997, 185: 55–64.
50. 50. P. Bagnarelli A. Valenza S. Menzo 1996 Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo J Virol 70 7603 7613 8892880 1:CAS:528:DyaK28Xmt1Gltb4%3D Bagnarelli P, Valenza A, Menzo S, et al.: Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J Virol 1996, 70: 7603–7613.
51. 51. K. Kure W.D. Lyman K.M. Weidenheim D.W. Dickson 1990 Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method Am J Pathol 136 1085 1092 1693470 1:STN:280:DyaK3c3nsVSmsg%3D%3D Kure K, Lyman WD, Weidenheim KM, Dickson DW: Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. Am J Pathol 1990, 136: 1085–1092.
52. 52. S. Aquaro P. Bagnarelli T. Guenci 2002 Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus J Med Virol 68 479 488 12376954 10.1002/jmv.10245 Aquaro S, Bagnarelli P, Guenci T, et al.: Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J Med Virol 2002, 68: 479–488.
53. 53. V. Mollace D. Salvemini D.P. Riley 2002 The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages J Leukoc Biol 71 65 72 11781381 1:CAS:528:DC%2BD38Xlt1aktw%3D%3D Mollace V, Salvemini D, Riley DP, et al.: The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages. J Leukoc Biol 2002, 71: 65–72.
54. 54. K.R. Robertson N. Nakasujja M. Wong 2007 Pattern of neuropsychological performance among HIV positive patients in Uganda BMC Neurol 7 8 17411437 10.1186/1471-2377-7-8 Robertson KR, Nakasujja N, Wong M, et al.: Pattern of neuropsychological performance among HIV positive patients in Uganda. BMC Neurol 2007, 7: 8.
55. 55. L.A. Cysique H. Jin D.R. Franklin Jr 2007 Neurobehavioral effects of HIV-1 infection in China and the United States: a pilot study J Int Neuropsychol Soc 13 781 790 17697409 Cysique LA, Jin H, Franklin DR Jr, et al.: Neurobehavioral effects of HIV-1 infection in China and the United States: a pilot study. J Int Neuropsychol Soc 2007, 13: 781–790.
56. 56. Laeyendecker O, Li X, Arroyo M, et al.: The effect of HIV subtype on rapid disease progression in Rakai, Uganda. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.
57. 57. K.J. Liner 2nd C.D. Hall K.R. Robertson 2007 Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease J Neurovirol 13 291 304 17849313 10.1080/13550280701422383 Liner KJ 2nd, Hall CD, Robertson KR: Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease. J Neurovirol 2007, 13: 291–304.
58. 58. N. Sacktor N. Nakasujja K. Robertson D.B. Clifford 2007 HIV-associated cognitive impairment in sub-Saharan Africa—the potential effect of clade diversity Nat Clin Pract Neurol 3 436 443 17671521 10.1038/ncpneuro0559 Sacktor N, Nakasujja N, Robertson K, Clifford DB: HIV-associated cognitive impairment in sub-Saharan Africa—the potential effect of clade diversity. Nat Clin Pract Neurol 2007, 3: 436–443.
59. 59. Sacktor N, Nakasujja N, Rezapour M, et al.: HIV subtype D is associated with a higher risk for dementia than subtype A in sub-Saharan Africa. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008.
60. 60. S.S. Spudich A.C. Nilsson N.D. Lollo 2005 Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment BMC Infect Dis 5 98 16266436 10.1186/1471-2334-5-98 Spudich SS, Nilsson AC, Lollo ND, et al.: Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005, 5: 98.
61. 61. Robertson K, Zhaouhui S, Krambrink A, et al.: This is your brain off drugs: neurocognitive function before and after antiretroviral treatment discontinuation in patients with high CD4 nadir. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.